Surgical treatment of ascending aortic aneurysms in patients with giant cell aortitis

Kenton J. Zehr, Alok Mathur, Thomas A. Orszulak, Charles J. Mullany, Hartzell V Schaff

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Background. Giant cell aortitis is a rare cause of ascending aortic aneurysm disease despite giant cell arteritis being a common cause of vasculitis. We evaluated an 8-year experience with surgical repair with regard to preoperative variables, extent of disease, required surgical procedures, and the propensity to develop additional great vessel aneurysms. Methods. Thirty-seven patients (29 female, 8 male; aged 69.6 ± 9.5 years) were operated on from 1995 to 2002. Ten (27%) patients had a history of steroid treatment for temporal arteritis or polymyalgia rheumatica 8.9 ± 3.9 years before. Nineteen (51%) patients had +3 or +4 aortic regurgitation. Maximal aneurysm size was 6.1 ± 0.8 cm. Thirty (81%) patients underwent polyethylene terephthalate fiber (Dacron) tube graft replacement of the ascending aorta, 4 (11%) had a modified Bentall procedure, 2 (5%) had a valve-sparing aortic root reconstruction, and 1 (3%) had aortorrhaphy. Twenty-two (59%) patients required 22 ± 9 minutes of hypothermic circulatory arrest for hemiarch or complete aortic arch replacement. Twenty-six (70%) patients had concomitant cardiac procedures. Results. There was no early mortality. Morbidity was reexploration for bleeding in 3 (8%) patients, stroke in 3 (8%), left vocal cord paralysis in 2 (5%), renal failure in 2 (5%), and gastrointestinal bleeding in 1 (3%). Mean follow-up was 2.8 ± 2.3 years. Four-year actuarial survival was 74% (95% confidence interval, 57% to 94%). Other descending or abdominal aortic or great vessel aneurysms occurred in 17 (46%) patients. Four patients had prior aneurysm surgery, 8 are monitored with aneurysms, and 5 underwent repair of an aneurysm in the follow-up period. Of 8 late deaths, 3 were caused by complications of a descending thoracic aneurysm. No patient required replacement of a native aortic valve that was preserved during the initial operative procedure. Conclusions. Ascending aortic aneurysms caused by giant cell aortitis can involve the aorta from the aortic root through the aortic arch, thus requiring a tailored operative approach. The aortic valve tissue is spared from the pathologic process. Other aneurysms of the aorta and great vessels occur in nearly half of patients. Frequent surveillance of the remaining aorta is mandatory.

Original languageEnglish (US)
Pages (from-to)1512-1517
Number of pages6
JournalAnnals of Thoracic Surgery
Volume79
Issue number5
DOIs
StatePublished - May 2005

Fingerprint

Giant Cell Arteritis
Aortic Aneurysm
Aneurysm
Aorta
Aortic Valve
Therapeutics
Polyethylene Terephthalates
Thoracic Aorta
Hemorrhage
Polymyalgia Rheumatica
Vocal Cord Paralysis
Aortic Diseases
Aortic Valve Insufficiency
Operative Surgical Procedures
Pathologic Processes
Vasculitis
Renal Insufficiency
Thorax
Stroke
Steroids

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Surgical treatment of ascending aortic aneurysms in patients with giant cell aortitis. / Zehr, Kenton J.; Mathur, Alok; Orszulak, Thomas A.; Mullany, Charles J.; Schaff, Hartzell V.

In: Annals of Thoracic Surgery, Vol. 79, No. 5, 05.2005, p. 1512-1517.

Research output: Contribution to journalArticle

Zehr, Kenton J. ; Mathur, Alok ; Orszulak, Thomas A. ; Mullany, Charles J. ; Schaff, Hartzell V. / Surgical treatment of ascending aortic aneurysms in patients with giant cell aortitis. In: Annals of Thoracic Surgery. 2005 ; Vol. 79, No. 5. pp. 1512-1517.
@article{8438fc2c0f1a4429a6472c6802c5205c,
title = "Surgical treatment of ascending aortic aneurysms in patients with giant cell aortitis",
abstract = "Background. Giant cell aortitis is a rare cause of ascending aortic aneurysm disease despite giant cell arteritis being a common cause of vasculitis. We evaluated an 8-year experience with surgical repair with regard to preoperative variables, extent of disease, required surgical procedures, and the propensity to develop additional great vessel aneurysms. Methods. Thirty-seven patients (29 female, 8 male; aged 69.6 ± 9.5 years) were operated on from 1995 to 2002. Ten (27{\%}) patients had a history of steroid treatment for temporal arteritis or polymyalgia rheumatica 8.9 ± 3.9 years before. Nineteen (51{\%}) patients had +3 or +4 aortic regurgitation. Maximal aneurysm size was 6.1 ± 0.8 cm. Thirty (81{\%}) patients underwent polyethylene terephthalate fiber (Dacron) tube graft replacement of the ascending aorta, 4 (11{\%}) had a modified Bentall procedure, 2 (5{\%}) had a valve-sparing aortic root reconstruction, and 1 (3{\%}) had aortorrhaphy. Twenty-two (59{\%}) patients required 22 ± 9 minutes of hypothermic circulatory arrest for hemiarch or complete aortic arch replacement. Twenty-six (70{\%}) patients had concomitant cardiac procedures. Results. There was no early mortality. Morbidity was reexploration for bleeding in 3 (8{\%}) patients, stroke in 3 (8{\%}), left vocal cord paralysis in 2 (5{\%}), renal failure in 2 (5{\%}), and gastrointestinal bleeding in 1 (3{\%}). Mean follow-up was 2.8 ± 2.3 years. Four-year actuarial survival was 74{\%} (95{\%} confidence interval, 57{\%} to 94{\%}). Other descending or abdominal aortic or great vessel aneurysms occurred in 17 (46{\%}) patients. Four patients had prior aneurysm surgery, 8 are monitored with aneurysms, and 5 underwent repair of an aneurysm in the follow-up period. Of 8 late deaths, 3 were caused by complications of a descending thoracic aneurysm. No patient required replacement of a native aortic valve that was preserved during the initial operative procedure. Conclusions. Ascending aortic aneurysms caused by giant cell aortitis can involve the aorta from the aortic root through the aortic arch, thus requiring a tailored operative approach. The aortic valve tissue is spared from the pathologic process. Other aneurysms of the aorta and great vessels occur in nearly half of patients. Frequent surveillance of the remaining aorta is mandatory.",
author = "Zehr, {Kenton J.} and Alok Mathur and Orszulak, {Thomas A.} and Mullany, {Charles J.} and Schaff, {Hartzell V}",
year = "2005",
month = "5",
doi = "10.1016/j.athoracsur.2004.10.039",
language = "English (US)",
volume = "79",
pages = "1512--1517",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Surgical treatment of ascending aortic aneurysms in patients with giant cell aortitis

AU - Zehr, Kenton J.

AU - Mathur, Alok

AU - Orszulak, Thomas A.

AU - Mullany, Charles J.

AU - Schaff, Hartzell V

PY - 2005/5

Y1 - 2005/5

N2 - Background. Giant cell aortitis is a rare cause of ascending aortic aneurysm disease despite giant cell arteritis being a common cause of vasculitis. We evaluated an 8-year experience with surgical repair with regard to preoperative variables, extent of disease, required surgical procedures, and the propensity to develop additional great vessel aneurysms. Methods. Thirty-seven patients (29 female, 8 male; aged 69.6 ± 9.5 years) were operated on from 1995 to 2002. Ten (27%) patients had a history of steroid treatment for temporal arteritis or polymyalgia rheumatica 8.9 ± 3.9 years before. Nineteen (51%) patients had +3 or +4 aortic regurgitation. Maximal aneurysm size was 6.1 ± 0.8 cm. Thirty (81%) patients underwent polyethylene terephthalate fiber (Dacron) tube graft replacement of the ascending aorta, 4 (11%) had a modified Bentall procedure, 2 (5%) had a valve-sparing aortic root reconstruction, and 1 (3%) had aortorrhaphy. Twenty-two (59%) patients required 22 ± 9 minutes of hypothermic circulatory arrest for hemiarch or complete aortic arch replacement. Twenty-six (70%) patients had concomitant cardiac procedures. Results. There was no early mortality. Morbidity was reexploration for bleeding in 3 (8%) patients, stroke in 3 (8%), left vocal cord paralysis in 2 (5%), renal failure in 2 (5%), and gastrointestinal bleeding in 1 (3%). Mean follow-up was 2.8 ± 2.3 years. Four-year actuarial survival was 74% (95% confidence interval, 57% to 94%). Other descending or abdominal aortic or great vessel aneurysms occurred in 17 (46%) patients. Four patients had prior aneurysm surgery, 8 are monitored with aneurysms, and 5 underwent repair of an aneurysm in the follow-up period. Of 8 late deaths, 3 were caused by complications of a descending thoracic aneurysm. No patient required replacement of a native aortic valve that was preserved during the initial operative procedure. Conclusions. Ascending aortic aneurysms caused by giant cell aortitis can involve the aorta from the aortic root through the aortic arch, thus requiring a tailored operative approach. The aortic valve tissue is spared from the pathologic process. Other aneurysms of the aorta and great vessels occur in nearly half of patients. Frequent surveillance of the remaining aorta is mandatory.

AB - Background. Giant cell aortitis is a rare cause of ascending aortic aneurysm disease despite giant cell arteritis being a common cause of vasculitis. We evaluated an 8-year experience with surgical repair with regard to preoperative variables, extent of disease, required surgical procedures, and the propensity to develop additional great vessel aneurysms. Methods. Thirty-seven patients (29 female, 8 male; aged 69.6 ± 9.5 years) were operated on from 1995 to 2002. Ten (27%) patients had a history of steroid treatment for temporal arteritis or polymyalgia rheumatica 8.9 ± 3.9 years before. Nineteen (51%) patients had +3 or +4 aortic regurgitation. Maximal aneurysm size was 6.1 ± 0.8 cm. Thirty (81%) patients underwent polyethylene terephthalate fiber (Dacron) tube graft replacement of the ascending aorta, 4 (11%) had a modified Bentall procedure, 2 (5%) had a valve-sparing aortic root reconstruction, and 1 (3%) had aortorrhaphy. Twenty-two (59%) patients required 22 ± 9 minutes of hypothermic circulatory arrest for hemiarch or complete aortic arch replacement. Twenty-six (70%) patients had concomitant cardiac procedures. Results. There was no early mortality. Morbidity was reexploration for bleeding in 3 (8%) patients, stroke in 3 (8%), left vocal cord paralysis in 2 (5%), renal failure in 2 (5%), and gastrointestinal bleeding in 1 (3%). Mean follow-up was 2.8 ± 2.3 years. Four-year actuarial survival was 74% (95% confidence interval, 57% to 94%). Other descending or abdominal aortic or great vessel aneurysms occurred in 17 (46%) patients. Four patients had prior aneurysm surgery, 8 are monitored with aneurysms, and 5 underwent repair of an aneurysm in the follow-up period. Of 8 late deaths, 3 were caused by complications of a descending thoracic aneurysm. No patient required replacement of a native aortic valve that was preserved during the initial operative procedure. Conclusions. Ascending aortic aneurysms caused by giant cell aortitis can involve the aorta from the aortic root through the aortic arch, thus requiring a tailored operative approach. The aortic valve tissue is spared from the pathologic process. Other aneurysms of the aorta and great vessels occur in nearly half of patients. Frequent surveillance of the remaining aorta is mandatory.

UR - http://www.scopus.com/inward/record.url?scp=18144366937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18144366937&partnerID=8YFLogxK

U2 - 10.1016/j.athoracsur.2004.10.039

DO - 10.1016/j.athoracsur.2004.10.039

M3 - Article

C2 - 15854925

AN - SCOPUS:18144366937

VL - 79

SP - 1512

EP - 1517

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 5

ER -